Michael Orth

List of Publications by Year
in descending order

36 papers	1,150 citations	516710 16 h-index	526287 27 g-index
36 all docs	36 docs citations	36 times ranked	1993 citing authors

#	Article	IF	Citations
1	Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiation Oncology, 2019, 14, 141.	2.7	285
2	Dying cell clearance and its impact on the outcome of tumor radiotherapy. Frontiers in Oncology, 2012, 2, 116.	2.8	152
3	Current concepts in clinical radiation oncology. Radiation and Environmental Biophysics, 2014, 53, 1-29.	1.4	143
4	Priming anti-tumor immunity by radiotherapy: Dying tumor cell-derived DAMPs trigger endothelial cell activation and recruitment of myeloid cells. OncoImmunology, 2019, 8, e1523097.	4.6	91
5	CDC-48/p97 Coordinates CDT-1 Degradation with GINS Chromatin Dissociation to Ensure Faithful DNA Replication. Molecular Cell, 2011, 44, 85-96.	9.7	88
6	HSP90 inhibition as a means of radiosensitizing resistant, aggressive soft tissue sarcomas. Cancer Letters, 2015, 365, 211-222.	7.2	40
7	Combination of 5-Fluorouracil with Epigenetic Modifiers Induces Radiosensitization, Somatostatin Receptor 2 Expression, and Radioligand Binding in Neuroendocrine Tumor Cells In Vitro. Journal of Nuclear Medicine, 2019, 60, 1240-1246.	5.0	35
8	A synthetic lethal screen identifies ATR-inhibition as a novel therapeutic approach for POLD1-deficient cancers. Oncotarget, 2016, 7, 7080-7095.	1.8	35
9	Shugoshin is a Mad1/Cdc20-like interactor of Mad2. EMBO Journal, 2011, 30, 2868-2880.	7.8	34
10	Taxane-mediated radiosensitization derives from chromosomal missegregation on tripolar mitotic spindles orchestrated by AURKA and TPX2. Oncogene, 2018, 37, 52-62.	5.9	31
11	Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. Radiation Oncology, 2020, 15, 5.	2.7	28
12	A novel HSP90 inhibitor with reduced hepatotoxicity synergizes with radiotherapy to induce apoptosis, abrogate clonogenic survival, and improve tumor control in models of colorectal cancer. Oncotarget, 2016, 7, 43199-43219.	1.8	24
13	Synergistic Highly Potent Targeted Drug Combinations in Different Pheochromocytoma Models Including Human Tumor Cultures. Endocrinology, 2019, 160, 2600-2617.	2.8	24
14	Early senescence and production of senescence-associated cytokines are major determinants of radioresistance in head-and-neck squamous cell carcinoma. Cell Death and Disease, 2021, 12, 1162.	6.3	23
15	Genomic amplification of Fanconi anemia complementation group A (FancA) in head and neck squamous cell carcinoma (HNSCC): Cellular mechanisms of radioresistance and clinical relevance. Cancer Letters, 2017, 386, 87-99.	7.2	21
16	Tumor-Specific Delivery of 5-Fluorouracil–Incorporated Epidermal Growth Factor Receptor–Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenocarcinoma Models. Gastroenterology, 2021, 161, 996-1010.e1.	1.3	20
17	NMR Screening for Lead Compounds Using Tryptophan-Mutated Proteins. Journal of Medicinal Chemistry, 2008, 51, 5035-5042.	6.4	12
18	Inhibition of HSP90 as a Strategy to Radiosensitize Glioblastoma: Targeting the DNA Damage Response and Beyond. Frontiers in Oncology, 2021, 11, 612354.	2.8	12

#	ARTICLE	IF	CITATIONS
19	The MTH1 inhibitor TH588 demonstrates anti-tumoral effects alone and in combination with everolimus, 5-FU and gamma-irradiation in neuroendocrine tumor cells. PLoS ONE, 2017, 12, e0178375.	2.5	10
20	GSK3α/β: A Novel Therapeutic Target for Neuroendocrine Tumors. Neuroendocrinology, 2018, 106, 335-351.	2.5	10
21	PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook. Frontiers in Oncology, 2021, 11, 774017.	2.8	10
22	Contrast-enhanced, conebeam CT-based, fractionated radiotherapy and follow-up monitoring of orthotopic mouse glioblastoma: a proof-of-concept study. Radiation Oncology, 2020, 15, 19.	2.7	8
23	Longitudinal [18F]GE-180 PET Imaging Facilitates In Vivo Monitoring of TSPO Expression in the GL261 Glioblastoma Mouse Model. Biomedicines, 2022, 10, 738.	3.2	8
24	Integrative analysis of therapy resistance and transcriptomic profiling data in glioblastoma cells identifies sensitization vulnerabilities for combined modality radiochemotherapy. Radiation Oncology, 2022, 17, 79.	2.7	3
25	OC-0220: Exploiting novel combined-modality approaches for treatment of highly aggressive pancreas carcinomas. Radiotherapy and Oncology, 2017, 123, S110.	0.6	1
26	In vitro evaluation of simulated stereotactic radiotherapy for wet age-related macular degeneration on three different cell lines. Scientific Reports, 2021, 11, 8068.	3.3	1
27	A Human Bone Marrow Failure Syndrome Caused By a Homozygous Mutation in MYSM1. Blood, 2015, 126, 1204-1204.	1.4	1
28	OC-0482: Paclitaxel at lower nanomolar concentrations sensitizes tumor cells to irradiation by inducing aneuploidy. Radiotherapy and Oncology, 2014, 111, S189.	0.6	0
29	OC-0441: Genomic amplification of FancA in HNSCC: mechanisms of radioresistance and clinical relevance. Radiotherapy and Oncology, 2016, 119, S205-S206.	0.6	0
30	OC-0488: Prognostic biomarkers and targets for personalization of radiotherapy of HNSCC: CD44v6. Radiotherapy and Oncology, 2018, 127, S251.	0.6	0
31	PO-0780 Prognostic value of PD-L1 expression in locally advanced NSCLC treated with chemoradiotherapy. Radiotherapy and Oncology, 2019, 133, S403.	0.6	0
32	Prognostic value of CD8-positive tumor stroma-infiltrating lymphocytes and PD-L1 positive tumor cells at initial biopsy in patients with locally advanced NSCLC treated with chemoradiotherapy. Annals of Oncology, 2019, 30, ii11.	1.2	0
33	Duktales Adenokarzinom des Pankreas: biologische Merkmale, Stand der Dinge und Ausblick auf multimodale Behandlungsansätze der Zukunft. Karger Kompass Onkologie, 2019, 6, 196-208.	0.0	0
34	Preclinical evaluation of F-18-PSMA PET in glioblastoma as a potential theranostic approach. , 2020, 59, .		0
35	PO-0999: Deciphering the tumor microenviroment based on PD-L1 expression and CD8 + TILs density in LA-NSCLC. Radiotherapy and Oncology, 2020, 152, S533.	0.6	0
36	Serial TSPO and FET PET monitoring in experimental orthotopic glioblastoma and the impact of inflammation and astrogliosis related to the inoculation process. Nuklearmedizin - NuclearMedicine, 2022, 61, .	0.7	0